Weihang Bao
Nanchang University(CN)Pfizer (United States)(US)First Affiliated Hospital of Jiangxi Medical College(CN)Second Affiliated Hospital of Nanchang University(CN)Inner Mongolia People's Hospital(CN)Yunnan University of Traditional Chinese Medicine(CN)
Publications by Year
Research Areas
Lipoproteins and Cardiovascular Health, Diabetes, Cardiovascular Risks, and Lipoproteins, Obesity, Physical Activity, Diet, Birth, Development, and Health, Cancer, Lipids, and Metabolism
Most-Cited Works
- → Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial(2002)4,145 cited
- → Association between Multiple Cardiovascular Risk Factors and Atherosclerosis in Children and Young Adults(1998)3,960 cited
- → Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease(2004)947 cited
- → Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis(2016)837 cited
- → Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: The Bogalusa heart study*(1995)765 cited
- → Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease(2006)547 cited